title: Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines.
abstract: Standard-of-care chemo- or radio-therapy can induce, besides tumor cell death, also tumor cell senescence. While senescence is considered to be a principal barrier against tumorigenesis, senescent cells can survive in the organism for protracted periods of time and they can promote tumor development. Based on this emerging concept, we hypothesized that elimination of such potentially cancer-promoting senescent cells could offer a therapeutic benefit. To assess this possibility, here we first show that tumor growth of proliferating mouse TC-1 HPV-16-associated cancer cells in syngeneic mice becomes accelerated by co-administration of TC-1 or TRAMP-C2 prostate cancer cells made senescent by pre-treatment with the anti-cancer drug docetaxel, or lethally irradiated. Phenotypic analyses of tumor-explanted cells indicated that the observed acceleration of tumor growth was attributable to a protumorigenic environment created by the co-injected senescent and proliferating cancer cells rather than to escape of the docetaxel-treated cells from senescence. Notably, accelerated tumor growth was effectively inhibited by cell immunotherapy using irradiated TC-1 cells engineered to produce interleukin IL-12. Collectively, our data document that immunotherapy, such as the IL-12 treatment, can provide an effective strategy for elimination of the detrimental effects caused by bystander senescent tumor cells in vivo.
authors.affiliation: Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
authors.forename: Jana
authors.initials: J
authors.lastname: Simova
authors.affiliation: Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
authors.forename: Olena
authors.initials: O
authors.lastname: Sapega
authors.affiliation: Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic.
authors.forename: Terezie
authors.initials: T
authors.lastname: Imrichova
authors.affiliation: Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
authors.forename: Ivan
authors.initials: I
authors.lastname: Stepanek
authors.affiliation: Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic.
authors.forename: Lenka
authors.initials: L
authors.lastname: Kyjacova
authors.affiliation: Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
authors.forename: Romana
authors.initials: R
authors.lastname: Mikyskova
authors.affiliation: Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
authors.forename: Marie
authors.initials: M
authors.lastname: Indrova
authors.affiliation: Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
authors.forename: Jana
authors.initials: J
authors.lastname: Bieblova
authors.affiliation: First Faculty of Medicine, Charles University in Prague, Prague 12000, Czech Republic.
authors.forename: Jan
authors.initials: J
authors.lastname: Bubenik
authors.affiliation: Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic.|Danish Cancer Society Research Center, Copenhagen DK-2100, Denmark.|Department of Medical Biochemistry and Biophysics, Science For Life Laboratory, Division of Translational Medicine and Chemical Biology, Karolinska Institute, 17121 Solna, Sweden.
authors.forename: Jiri
authors.initials: J
authors.lastname: Bartek
authors.affiliation: Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic.
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Hodny
authors.affiliation: Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
authors.forename: Milan
authors.initials: M
authors.lastname: Reinis
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D024201:Bystander Effect / Q000187:drug effects; D045744:Cell Line, Tumor; D016922:Cellular Senescence / Q000187:drug effects*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D000077143:Docetaxel; D016219:Immunotherapy, Adoptive / Q000379:methods*; D018664:Interleukin-12 / Q000096:biosynthesis / Q000494:pharmacology*; D008297:Male; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D043823:Taxoids / Q000494:pharmacology*; D013997:Time Factors; D047368:Tumor Burden / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D016207:Cytokines; D043823:Taxoids; D000077143:Docetaxel; D018664:Interleukin-12
keywords: IL-12; cancer chemotherapy; cell therapy; cellular senescence; docetaxel